hCG is not an alternative to eCG in the TAI protocol in Bos indicus cows, but it increases the efficiency of TAI protocols in cows that do not show estrus

Article

Author: Carvalho, Laís Reis ; Ayres, Henderson ; Lemos, Lucas Araujo ; Teixeira, Leonardo ; de Sousa Sales, José Nélio ; Vicente, Matheus Pedroso ; de Souza, José Camisão ; Dos Reis, Kaio Batista ; Mingoti, Rodolfo Daniel ; Vieira, Laís Mendes ; Simões, Luiz Manoel Souza

The study evaluated the use of hCG at different times in the TAI protocol on the fertility of Bos indicus cows. In Experiment 1, cows received a progesterone device and 2 mg of estradiol benzoate (EB) on D0. The device was removed on D8.5 (study A) or D7 (study B), followed by 500 µg of cloprostenol and 1 mg of EB or estradiol cypionate. At this moment, cows were assigned to Control (no treatment), eCG (300 IU), or hCG (150 IU) groups. TAI occurred 36 h (A) or 48 h (B) post-device removal. In Experiment 2, in studies A and B, treatments [Control, GnRH (100 µg), or hCG (1000 IU)] were administered at TAI. In study C, cows received or did not receive 500, 800, or 1000 IU of hCG at TAI. In Experiment 1, cows of the control group had lower follicular growth (P < 0.01), and cows of the hCG group had greater estrus expression (P = 0.006) and early ovulation (P = 0.001). However, the cows of the hCG and control groups had lower P/AI (P = 0.01). In Experiment 2, cows of the hCG group had greater ovulation rates (P = 0.03) and pregnancy rates (P = 0.04). In study C, 1000 IU of hCG at TAI increased (tendency) the fertility (P = 0.07). In conclusion, hCG is not an effective alternative to eCG at device removal. However, 1000 IU of hCG at the time of insemination improves fertility in cows that did not express estrus.

01 Apr 2026·THERIOGENOLOGY

Reproductive efficiency of Nelore (Bos indicus) cows submitted to conventional resynchronization or ReBreed21 programs

Article

Author: Colli, Marcos H A ; Prata, Alexandre B ; Alves, Rodrigo L O R ; Azevedo, Tainá L P ; Consentini, Carlos E C ; Silva, Lucas O E ; Sartori, Roberto ; Balistrieri, Mirela ; Cortat, Paula R ; Gonçalves, José R

The aims were to evaluate the reproductive efficiency of Nelore (Bos indicus) cows submitted to resynchronization programs for timed artificial insemination (TAI) and to evaluate the effect of estradiol cypionate dose (EC; 0.5 vs. 1.0 mg) on reproductive outcomes in a ReBreed21 program. A total of 253 primiparous and 645 multiparous cows (3.0 ± 0.4 of body condition score and 51 ± 13.7 days postpartum) were assigned to one of three resynchronization strategies: conventional (Resynch33; n = 299), ReBreed21 with 0.5 mg of EC (REB0.5; n = 299), or ReBreed21 with 1.0 mg of EC (REB1.0; n = 300). All cows received the same synchronization protocol for the first AI (Day 0). On Day 12 after the first TAI, cows in ReBreed21 treatments received a P4 device (0.5 g), which remained until Day 19, when 300 IU of equine chorionic gonadotropin (eCG) and either 0.5 or 1.0 of mg EC were administered. On Day 21, early pregnancy diagnosis was performed in all cows by corpus luteum perfusion evaluation using color Doppler ultrasonography; nonpregnant cows in ReBreed21 received 8.4 μg of GnRH and underwent the second AI. On Day 33, pregnancy was confirmed, and cows in ReBreed21 inseminated on Day 21 were resubmitted to the same ReBreed21 protocol to receive a third AI on Day 42. Cows diagnosed as pregnant on Day 21 but nonpregnant on Day 33 were considered false positives (FP) and, like those in Resynch33, were resubmitted on Day 33 for the second AI on Day 42 to the same TAI protocol that was used for first AI. Ultrasound examinations were performed on Day 54 and Day 75 to assess pregnancy per AI (P/AI), FP, and pregnancy loss (PL). Statistical analyses were done using SAS 9.4. Significance was declared at P ≤ 0.05, and tendencies when 0.05 < P ≤ 0.10. The P/AI, FP, and PL did not differ between ReBreed21 treatments. After 21 days of the breeding season (BS), the pregnancy rate (PR) was greater in REB1.0 (77.7 %) and REB0.5 (75.4 %) than in Resynch33 (52.8 %; P < 0.0001), although final PR was similar among REB1.0 (84.7 %), REB0.5 (84.9 %), and Resynch33 (79.9 %). Time to pregnancy was shorter (P < 0.0001) in REB1.0 (8.5 days) and REB0.5 (10.8 days) than Resynch33 (15.8 days). Regardless of EC dose, ReBreed21 increased PR after Day 0 (59.9 vs. 52.8 %; P = 0.03) and Day 21 (76.6 vs. 52.8 %; P < 0.0001), and improved PR on Day 42 (84.8 vs. 79.9 %; P = 0.06). The incidence of FP was greater in Resynch33 than ReBreed21 (13.7 vs. 7.5 %; P = 0.02), but final PL did not differ (3.2 vs. 3.1 %). In conclusion, the ReBreed21 program anticipated pregnancies, improved PR, and reduced FP, highlighting its potential to enhance reproductive efficiency in Nelore cows. The dose of 1.0 mg of EC had no effect on fertility parameters.

01 Mar 2026·THERIOGENOLOGY

Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates

Article

Author: Pessoa, Gilson Antônio ; Gallas Leivas, Fábio ; Martini, Ana Paula ; Rohde Brondani, Camila ; Dos Santos Brum, Daniela ; Rohde Brondani, Laura

The aim of this study was to evaluate the use of buserelin acetate, a GnRH analog, in combination with estradiol benzoate (EB) at the beginning of an early resynchronization protocol (R22) in Bos taurus beef heifers. A total of 656 heifers underwent a first fixed-time artificial insemination (FTAI; designated as D0) and received a reused intravaginal progesterone (P4; 1 g) device on D22. At that time, heifers were randomized into two treatment groups: EB (1 mg; n = 329) or GnRH + EB (1 mg of EB plus 10 μg of buserelin acetate; n = 327). On D30, the P4 device was removed, and a pregnancy diagnosis was performed. Non-pregnant heifers (EB = 152/329; GnRH + EB = 134/327) received 200 IU of equine chorionic gonadotropin, 1 mg of estradiol cypionate and 0.5 mg of cloprostenol sodium, followed by a second FTAI on D32. A subset of heifers underwent ovarian ultrasonography on D22 (n = 463), D30 (n = 193), and D32 (n = 165); a second pregnancy diagnosis was performed on D62. Heifers treated with EB alone had larger dominant follicles on both D30 and D32 (P = 0.0001) and a higher incidence of early ovulation before FTAI compared to GnRH + EB group (18.9 % vs. 8.8 %; P = 0.03). The GnRH + EB group achieved a superior pregnancy rate at R22 (EB = 40.8 % vs. GnRH + EB = 56.0 %; P = 0.008) and a higher cumulative pregnancy rate (EB = 68.4 % vs. GnRH + EB = 79.2 %; P = 0.01). In conclusion, the administration of 10 μg of buserelin acetate combined with 1 mg of EB at the beginning of the R22 protocol improved conception rates in Bos taurus beef heifers.

News (Medical) associated with Estradiol Cypionate

21 Apr 2026

·www.prnewswire.com

ProRx Pharma Continues to Grow Operational Footprint, Triples Production Capacity to Support Demand for Compounded Medications

Facility Expansion, Automation Investments, and Workforce Additions Drive Growth EXTON, Pa., April 21, 2026 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced a period of significant growth, including increased production capacity, a larger facility footprint, and expanded delivery capabilities into two new states, Oklahoma and Virginia, with additional states expected in the coming months. Over the past several months, ProRx has expanded its physical footprint from approximately 3,400 square feet to approximately 17,000 square feet. The space now includes additional clean rooms and specialized environments for sterile and non-sterile hazardous, and non-hazardous drug production with further buildouts underway. This expansion has directly supported a significant increase in production output. Monthly production has grown substantially since December, with additional increases expected in the coming months. "We've tripled production capacity in a relatively short period of time, but that growth is the result of deliberate investment," said Kurt Lunkwitz, chief operating officer at ProRx Pharma. "Our focus has been on building the infrastructure required to scale in a controlled way while maintaining quality and consistency across our operations." To support this growth, ProRx has made targeted investments in automation and quality systems. These include an AI-based visual inspection system designed to evaluate product consistency across large batches, as well as additional aseptic filling equipment to further expand capacity. In addition, the company is adding a sterile hazardous drug clean room to support the production of an expanded Hormone Replacement Therapy (HRT) portfolio. The company has also invested in voluntary training through the Parenteral Drug Association (PDA), including programs focused on visual inspection, aseptic technique, and quality systems, with internal trainers extending that knowledge across the organization. Workforce growth has followed alongside the operational investments with staffing approximately doubling in recent months. ProRx has added pharmacists, quality-control, and operational roles to support increased production demands, along with several corporate support staff in HR and IT. Looking forward, ProRx is preparing to expand its product portfolio with new injectable preparations that include Testosterone and Estradiol Cypionate, targeted for release in the coming months. About ProRx Pharma ProRx Pharma is an FDA-registered, cGMP 503B outsourcing facility committed to delivering compliant, high-quality compounded preparations to physician practices, medical clinics, and med spas across the country. With a focus on regulatory alignment, operational reliability, and customer service, ProRx partners with providers to support access to essential therapies. For more information, connect with ProRx on LinkedIn or visit . SOURCE ProRx Pharma 21% more press release views with Request a Demo

100 Deals associated with Estradiol Cypionate

External Link

KEGG	Wiki	ATC	Drug Bank
D04063	Estradiol Cypionate	G03CA03	DB13954

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Oestrogen deficiency	United States	Pfizer Inc.	15 Aug 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis